Thanks PoS,
I was thinking that its not only investors who might be having trouble adjusting to the new paradigm of Phylogica as a global leader.
A deal in February may not have been as lucrative as a deal in April. I don't think the analogy of a bird in the hand applies when the technology is attracting world-wide attention.
In the brave new world of intracellular drug delivery the economics of licencing FPPs might be growing in value. With $6m in the bank and Hopkins running the show, I'm happy to wait.
Thanks PoS,I was thinking that its not only investors who might...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.26 |
Change
-0.035(2.70%) |
Mkt cap ! $734.9M | |||
| Open | High | Low | Value | Volume |
| $1.31 | $1.31 | $1.26 | $2.681M | 2.075M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3081 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.30 | 700 | 1 |
View Market Depth
| Last trade - 16.11pm 28/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |